What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. Its amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. First isolated and characterized in the early 1990s, it has since become one of the most extensively studied peptides in preclinical tissue repair research.
Mechanisms of Action
The literature suggests that BPC-157 operates through multiple interconnected pathways:
Angiogenesis and VEGF Modulation
Sikiric et al. (2018) demonstrated that BPC-157 promotes angiogenesis—the formation of new blood vessels—through upregulation of vascular endothelial growth factor (VEGF) and its receptor VEGFR2. This pro-angiogenic effect is believed to be a primary mechanism by which the peptide supports tissue repair, as adequate blood supply is essential for wound healing.
Nitric Oxide System
Research published in Current Pharmaceutical Design (Sikiric et al., 2014) has shown that BPC-157 interacts with the nitric oxide (NO) system, potentially mediating vasodilation and cytoprotection. The peptide appears to modulate both endothelial NOS (eNOS) and inducible NOS (iNOS) expression depending on the tissue context.
Growth Factor Regulation
Studies by Huang et al. (2015) in the Journal of Orthopaedic Research documented that BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, suggesting a mechanism for its observed effects on connective tissue repair. Additional research has shown modulation of EGF, FGF, and TGF-beta signaling pathways.
Preclinical Evidence: Tissue Repair
Tendon and Ligament
Chang et al. (2011) published in the Journal of Applied Physiology that BPC-157 accelerated healing of transected Achilles tendons in rat models, with treated groups showing superior biomechanical properties at 14 days post-injury compared to controls. The peptide promoted organized collagen fiber formation and increased type I collagen expression.
Gastrointestinal Protection
As a gastric peptide, BPC-157 has shown consistent cytoprotective effects across the GI tract. Sikiric et al. (1999) in the Journal of Physiology Paris demonstrated protection against ethanol-induced gastric lesions, NSAID-induced intestinal damage, and various models of inflammatory bowel disease. The peptide maintained mucosal integrity and accelerated ulcer healing.
Musculoskeletal Repair
Pevec et al. (2010) reported in Journal of Orthopaedic Research that systemic BPC-157 administration improved healing of segmental bone defects in rabbit models, with enhanced callus formation and earlier bone union compared to control groups.
Stability and Administration
One notable property of BPC-157 is its stability in human gastric juice, a characteristic unusual among peptides. Sikiric et al. (2013) noted that this stability may underlie its efficacy when administered orally in research models—most peptides are rapidly degraded by gastric acid and proteolytic enzymes.
Limitations and Future Directions
It is important to note that the vast majority of BPC-157 research has been conducted in animal models. No large-scale human clinical trials have been completed to date. The peptide's mechanisms of action, while extensively studied, are complex and not yet fully elucidated. Researchers should interpret preclinical findings with appropriate caution and within the context of established scientific methodology.
References:
Sikiric P, et al. (2018). "Stable gastric pentadecapeptide BPC 157 and wound healing." Front Pharmacol. 9:1238.
Sikiric P, et al. (2014). "BPC 157 and standard angiogenic growth factors." Curr Pharm Des. 20(7):1014-29.
Huang T, et al. (2015). "BPC-157 and tendon healing." J Orthop Res. 33(8):1098-1107.
Chang CH, et al. (2011). "BPC-157 and Achilles tendon healing." J Appl Physiol. 110(3):774-80.
Sikiric P, et al. (1999). "Gastric pentadecapeptide BPC 157 and gastrointestinal tract." J Physiol Paris. 93(6):501-5.
Pevec D, et al. (2010). "BPC-157 and bone healing." J Orthop Res. 28(8):1155-61.
This article is intended for informational and educational purposes only. ROEHN products are sold strictly for in-vitro research use and are not intended for human consumption. Always consult published literature and institutional protocols before designing any research protocol.